• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

伊朗的毛霉病:一项系统评价。

Mucormycosis in Iran: a systematic review.

作者信息

Vaezi Afsane, Moazeni Maryam, Rahimi Mohammad Taghi, de Hoog Sybren, Badali Hamid

机构信息

Student Research Committee, Mazandaran University of Medical Sciences, Sari, Iran.

Department of Medical Mycology and Parasitology/Invasive Fungi Research Center (IFRC), School of Medicine, Mazandaran University of Medical Sciences, Sari, Iran.

出版信息

Mycoses. 2016 Jul;59(7):402-15. doi: 10.1111/myc.12474. Epub 2016 Feb 15.

DOI:10.1111/myc.12474
PMID:26906121
Abstract

Fungi in the order Mucorales cause acute, invasive and frequently fatal infections in susceptible patients. This study aimed to perform a systematic review of all reported mucormycosis cases during the last 25 years in Iran. After a comprehensive literature search, we identified 98 cases in Iran from 1990-2015. The mean patient age was 39.8 ± 19.2 years. Diabetes was the most common underlying condition (47.9%), and 22.4% of the patients underwent solid organ or bone marrow transplantation. The most common clinical forms of mucormycosis were rhinocerebral (48.9%), pulmonary (9.2%) and cutaneous (9.2%). Eight cases of disseminated disease were identified. Overall mortality in the identified cases was 40.8%, with the highest mortality rate in patients diagnosed with disseminated infection (75%). The mortality rate in rhinocerebral infection patients was significantly lower (45.8%). Rhinocerebral infection was the most common clinical manifestation in diabetes patients (72.9%). Patients were diagnosed using various methods including histopathology (85.7%), microscopy (12.3%) and culture (2.0%). Rhizopus species were the most prevalent (51.7%), followed by Mucor species (17.2%). Sixty-nine patients were treated with a combination of surgery and antifungal therapy (resulting survival rate, 66.7%). Owing to the high mortality rate of advanced mucormycosis, early diagnosis and treatment may significantly improve survival rates. Therefore, increased monitoring and awareness of this life-threatening disease is critical.

摘要

毛霉目真菌可在易感患者中引发急性、侵袭性且常为致命性的感染。本研究旨在对伊朗过去25年中所有报告的毛霉病病例进行系统综述。经过全面的文献检索,我们在伊朗确定了1990年至2015年期间的98例病例。患者的平均年龄为39.8±19.2岁。糖尿病是最常见的基础疾病(47.9%),22.4%的患者接受了实体器官或骨髓移植。毛霉病最常见的临床类型为鼻脑型(48.9%)、肺型(9.2%)和皮肤型(9.2%)。确定了8例播散性疾病病例。所确定病例的总体死亡率为40.8%,播散性感染患者的死亡率最高(75%)。鼻脑型感染患者的死亡率显著较低(45.8%)。鼻脑型感染是糖尿病患者中最常见的临床表现(72.9%)。患者通过多种方法进行诊断,包括组织病理学(85.7%)、显微镜检查(12.3%)和培养(2.0%)。根霉属是最常见的(51.7%),其次是毛霉属(17.2%)。69例患者接受了手术和抗真菌治疗联合方案(生存率为66.7%)。由于晚期毛霉病的高死亡率,早期诊断和治疗可能显著提高生存率。因此,加强对这种危及生命疾病的监测和认识至关重要。

相似文献

1
Mucormycosis in Iran: a systematic review.伊朗的毛霉病:一项系统评价。
Mycoses. 2016 Jul;59(7):402-15. doi: 10.1111/myc.12474. Epub 2016 Feb 15.
2
Utility of Mucorales polymerase chain reaction to diagnose Rhizomucor infections in neutropenic patients.毛霉目聚合酶链反应在诊断中性粒细胞减少患者根霉感染中的应用。
Med Mycol. 2025 Jan 25;63(2). doi: 10.1093/mmy/myaf013.
3
Chronic cutaneous and mucosal mucormycosis: as a major pathogenic fungus.慢性皮肤和黏膜毛霉病:作为一种主要的致病真菌。
Emerg Microbes Infect. 2025 Dec;14(1):2477653. doi: 10.1080/22221751.2025.2477653. Epub 2025 Mar 18.
4
Mucormycosis caused by Apophysomyces species: An experience from a tertiary care hospital in Western India and systematic review of global cases.阿波菲霉属引起的毛霉病:来自印度西部一家三级护理医院的经验及全球病例的系统评价
Mycoses. 2023 Mar;66(3):181-195. doi: 10.1111/myc.13538. Epub 2022 Oct 20.
5
Bone and joint infections caused by mucormycetes: A challenging osteoarticular mycosis of the twenty-first century.毛霉菌引起的骨与关节感染:21世纪具有挑战性的骨关节炎性真菌病。
Med Mycol. 2017 Oct 1;55(7):691-704. doi: 10.1093/mmy/myw136.
6
Mucormycosis following burn injuries: A systematic review.烧伤后毛霉菌病:一项系统综述。
Burns. 2023 Feb;49(1):15-25. doi: 10.1016/j.burns.2022.05.012. Epub 2022 May 13.
7
The burden of mucormycosis in HIV-infected patients: A systematic review.HIV 感染者中毛霉菌病的负担:系统评价。
J Infect. 2016 Sep;73(3):181-8. doi: 10.1016/j.jinf.2016.06.013. Epub 2016 Jul 7.
8
Detection of antigen in bronchoalveolar lavage samples using a newly developed lateral-flow device.使用新开发的侧向流动装置检测支气管肺泡灌洗样本中的抗原。
J Clin Microbiol. 2025 Jun 18:e0022625. doi: 10.1128/jcm.00226-25.
9
Gastrointestinal mucormycosis: A periodic systematic review of case reports from 2015 to 2021.胃肠道毛霉菌病:2015 年至 2021 年病例报告的定期系统回顾。
Microb Pathog. 2022 Feb;163:105388. doi: 10.1016/j.micpath.2022.105388. Epub 2022 Jan 4.
10
Antifungal agents for preventing fungal infections in non-neutropenic critically ill patients.用于预防非中性粒细胞减少的重症患者真菌感染的抗真菌药物。
Cochrane Database Syst Rev. 2016 Jan 16;2016(1):CD004920. doi: 10.1002/14651858.CD004920.pub3.

引用本文的文献

1
Analysis of the clinical parameters and management aspects of rhino-maxillary mucormycosis, Part I: challenges in diagnosis.鼻上颌毛霉菌病的临床参数及管理方面分析,第一部分:诊断挑战
BMC Oral Health. 2025 Jul 31;25(1):1286. doi: 10.1186/s12903-025-05842-5.
2
One-Year Patient Survival After COVID-19-Associated Rhino-Orbital-Cerebral Mucormycosis: A Multicenter Study.新型冠状病毒肺炎相关鼻眶脑型毛霉病后的患者一年生存率:一项多中心研究
Mycopathologia. 2025 Jul 6;190(4):63. doi: 10.1007/s11046-025-00966-2.
3
Molecular epidemiology, diversity, and antifungal susceptibility profiles of clinical and environmental mucorales: a five-year multicenter study in Iran (2018-2023).
临床和环境毛霉目真菌的分子流行病学、多样性及抗真菌药敏谱:伊朗一项为期五年的多中心研究(2018 - 2023年)
BMC Infect Dis. 2025 Jul 1;25(1):849. doi: 10.1186/s12879-025-11189-7.
4
Survival and prognostic factors in rhino-orbito-cerebral mucormycosis: A 3-year cohort study.鼻眶脑型毛霉菌病的生存及预后因素:一项为期3年的队列研究。
Sci Rep. 2025 May 8;15(1):16088. doi: 10.1038/s41598-025-98926-9.
5
Impact of COVID-19 on mucormycosis presentation and laboratory values: A comparative analysis.2019冠状病毒病对毛霉菌病表现及实验室检查值的影响:一项对比分析。
PLoS One. 2025 May 2;20(5):e0321897. doi: 10.1371/journal.pone.0321897. eCollection 2025.
6
The Contribution of Human Antimicrobial Peptides to Fungi.人类抗菌肽对真菌的作用
Int J Mol Sci. 2025 Mar 11;26(6):2494. doi: 10.3390/ijms26062494.
7
Estimation of the pattern of ocular manifestations, risk factors, and imaging of rhino-orbital-cerebral mucormycosis in COVID-19 patients.新型冠状病毒肺炎患者鼻眶脑型毛霉菌病眼部表现模式、危险因素及影像学评估
J Family Med Prim Care. 2025 Jan;14(1):259-267. doi: 10.4103/jfmpc.jfmpc_1161_24. Epub 2025 Jan 13.
8
Epidemiological Trends of Mucormycosis in Europe, Comparison with Other Continents.欧洲毛霉菌病的流行病学趋势,与其他大洲的比较。
Mycopathologia. 2024 Nov 20;189(6):100. doi: 10.1007/s11046-024-00907-5.
9
Epidemiology, pathogenesis, clinical characteristics, and treatment of mucormycosis: a review.棘白菌素类药物在侵袭性曲霉菌病治疗中的作用。
Ann Med. 2024 Dec;56(1):2396570. doi: 10.1080/07853890.2024.2396570. Epub 2024 Sep 2.
10
Clinical characteristics and mortality of mucormycosis in hematological malignancies: a retrospective study in Eastern China.中国东部地区血液恶性肿瘤患者中毛霉菌病的临床特征和死亡率:一项回顾性研究。
Ann Clin Microbiol Antimicrob. 2024 Aug 29;23(1):82. doi: 10.1186/s12941-024-00738-8.